LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus subsidiary SaponiQx, a leader in saponin-based adjuvant production and discovery, today announced an agreement to supply InvivoGen with STIMULON cultured plant cell (cpc) QS-21. SaponiQx’s STIMULON™ QS-21 is a key adjuvant component in market-leading vaccines for shingles, malaria, and respiratory syncytial virus.

马萨诸塞州列克星敦市。-（商业新闻短讯）--Agenus子公司SaponiQx是基于皂苷的佐剂生产和发现的领导者，今天宣布了一项协议，为InvivoGen提供刺激培养的植物细胞（cpc）QS-21。SasioQX的STIMULON™QS-21是市场领先的带状疱疹、疟疾和呼吸道合胞病毒疫苗的关键佐剂成分。

CpcQS-21 is derived from a cultured plant cell source, offering a sustainable alternative to conventional QS-21 extracted from a limited supply of tree bark..

CpcQS-21来源于培养的植物细胞来源，为从有限供应的树皮中提取的常规QS-21提供了可持续的替代品。。

Key Highlights:

主要亮点：

SaponiQx will manufacture cpcQS-21, under the terms of the agreement, to InvivoGen, who will market the product to labs, academic institutions, and industry partners through its international retail infrastructure.

根据协议条款，SasioQX将向InvivoGen生产cpcQS-21，InvivoGen将通过其国际零售基础设施向实验室、学术机构和行业合作伙伴销售该产品。

Scalable Production: With the capability to produce kilograms of material at scale, the SaponiQx platform has the potential to significantly bolster the global vaccine supply chain by making pandemic quantity vaccines more accessible.

可扩展生产：凭借大规模生产公斤材料的能力，SAPOIQX平台有可能通过使大流行数量的疫苗更容易获得，从而显着支持全球疫苗供应链。

Innovation in Adjuvant Discovery: SaponiQx recently successfully kicked off the next phase of their adjuvant discovery program merging synthetic biology with Generative AI-enabled molecular design. With this, SaponiQx will target new saponin adjuvants intended to pair adjuvant and antigens, in a bespoke manner, for fine-tuned vaccine efficacy..

佐剂发现的创新：SasioQX最近成功启动了佐剂发现计划的下一阶段，将合成生物学与生成性人工智能分子设计相结合。这样，SasioQX将针对新的皂苷佐剂，旨在以定制的方式将佐剂和抗原配对，以微调疫苗功效。。

“This agreement is an important step in bringing cpcQS-21 to market for the first time and underscores our ability to produce cpcQS-21 adjuvant without reliance on the traditional tree-bark extract process,” said Rebecca Kurnat, Head of Operations at SaponiQx. “The availability of cpcQS-21 will accelerate the ability of labs, academic institutions, and industry to study the applications and potential of our adjuvant.

Sasiqx运营主管丽贝卡·库纳特（RebeccaKurnat）表示：“这项协议是首次将cpcQS-21推向市场的重要一步，突显了我们在不依赖传统树皮提取工艺的情况下生产cpcQS-21佐剂的能力。”。“cpcQS-21的可用性将加速实验室，学术机构和行业研究我们佐剂的应用和潜力的能力。

We look forward to partnering with InvivoGen to pioneer the cpcQS-21 market, making this powerful product broadly available to the adjuvant research community.”.

我们期待着与InvivoGen合作，开拓cpcQS-21市场，使这种强大的产品广泛提供给佐剂研究界。”。

“We are excited to collaborate with SaponiQx, who shares our passion for innovation to accelerate the discovery and development of novel vaccines,” said Eric Perouzel, Chief Operating Officer at InvivoGen. “Helping researchers worldwide to access QS-21 is vital, and it is our responsibility to select a sustainable source of this product.

InvivoGen首席运营官埃里克·佩鲁泽尔（EricPerouzel）表示：“我们很高兴与SasioQX合作，他们与我们一样热衷于创新，以加速新型疫苗的发现和开发。”。“帮助世界各地的研究人员获得QS-21至关重要，我们有责任选择这种产品的可持续来源。

We are very proud to be able to offer this next-generation adjuvant in the near future.”.

我们非常自豪能够在不久的将来提供这种下一代佐剂。”。

About SaponiQx

关于SANIQX

Founded in 2021, SaponiQx, a subsidiary of Agenus Inc., stands at the forefront of saponin-based adjuvant discovery and manufacturing. Its mission is to provide scalable and affordable vaccine adjuvants to enhance global health. Its proprietary adjuvant, STIMULON QS-21, forms an integral part of the AS01 adjuvant used in several leading vaccines.

Agenus Inc.的子公司SasioQX成立于2021年，在基于皂苷的佐剂发现和制造方面处于领先地位。其使命是提供可扩展且价格合理的疫苗佐剂，以增进全球健康。其专有佐剂STIMULON QS-21是几种主要疫苗中使用的AS01佐剂的组成部分。

STIMULON is a trademark of Agenus Inc., the parent company of SaponiQx Inc..

STIMULON是Sasioqx Inc.的母公司Agenus Inc.的商标。